BACKGROUND: Standard methods of mutation detection are time consuming in Hemophilia A (HA) rendering their application unavailable in some analysis such as prenatal diagnosis.
3.1 kb (exon 14) in size, spans 186 kb of genomic DNA and produces a 9030 nt mRNA. According to the UK Hemophilia Centre Doctors' Organisation (UKHCDO) Hemophilia Genetics Laboratory Network, the severity of HA in the pedigree should be determined Þ rst as this will inß uence the diagnostic strategy to be employed.
Severe Hemophiliacs should be screened for the intron 22 inversion mutation followed by the intron 1 inversion mutation. This approach identiÞ es the underlying mutation in 45-50% of severe HA patients. [3, 4] The remaining severe HA pedigrees should then be analyzed further either by full mutation or linkage analysis. Mutations have been found in nearly all 26 exons of the factor VIII gene, over 400 mutations have been identiÞ ed [5, 6] and de novo mutations represent approximately 30% of all cases. [7] The most common detection methods include DNA sequence analysis which requires numerous reactions and individual analysis of each exon or alternative screening methods such as singlestranded conformation polymorphism (SSCP), [8] denaturing gradient gel electrophoresis (DGGE) [8] and denaturing high performance liquid chromatography (dHPLC). [9] We applied the new combinatorial sequencingby-hybridization (cSBH) as an alternative method to the traditional Sanger dideoxy chain termination approach. [10, 11] Previous works have shown that cSBH is an efÞ cient rapid and alternative method for mutation detection. [12, 13] We increased the quality of results with a new cSBH method that use two different colors (TAMRA and We report development of a strategy to implement 2-color cSBH to screen a range of mutations within the FVIII gene.
Materials and Methods

Sample
After approval of the local ethics committee, the study was carried out according to the Principles of the Declaration of Helsinki. After informed consent the genomic DNA was isolated from clinically diagnosed individuals with HA, regularly investigated for the detection of the causative mutation within the F8 gene.
Samples were labelled using an internal lab code. We selected samples that presented a point mutation at different position in the F8 gene. We selected samples 1 and 20, which present a nonsense mutation; samples 73 and 95, which present a 2 bp deletion; samples 2, 6, 37, and 89, which present a single bp deletion;
and a series of randomly selected samples in which a missense mutation was identiÞ ed. Samples 1 and 20 and 2, 6, and 37 carry the same mutation and were used to verify the quality of results in the analysis. In addition,
we randomly selected 7 HA male patients, who were previously excluded to carry the inversion of the intron 1 or of the intron 22 and in whom no gene mutation was detected by a Þ rst FVIII gene screening, using common strategies (SSCP, DGGE, or dHPLC). All the patients involved in this study are regularly followed at one of 50 
Primer design
Primers for multiplex and nested PCR were obtained from MWG Deutschland, (HPLC puriÞ ed) and designed using Primer 3 software (www.genome.wi.mit.edu/cgibin/primer/primer3_www.cgi) to span the entire HA gene coding regions with intron-exon boundary coverage.
DNA amplifi cation
The ampliÞ cation of target for cSBH was performed in two consecutive steps [ 
Target preparation
Prior to hybridization, the PCR nested-asymmetric products were precipitated using isopropanol, creating eight different mixes containing single-stranded DNA of the forward and eight containing the reverse strand. The mixes were performed to optimize the analysis results.
We created eight different mixes as follow: exons 1 to 5, exons 6 to 9, exons 10 to17, exons 18 to 25, overlapping fragments 14a, 14b, 14c separately and fragments 26a and 26b in the same mix. 
Mutation Detection in Italian Haemophilic A Patients
A total of 16 clinically diagnosed Italian haemophilic A patients and one obligate carrier previously genotyped Table 2 . We conÞ rmed single-base changes in samples 1, 20, 64, 65, 80, 88, 90, 93, 99 . Previous genotyping of samples 2 [ Figure 2A ], 3 [ Figure 2B ], 37, and 89 carrying a singlebase deletion in exon 14 (fragment b) as well as in sample 6 [ Figure 2C ] containing a single deletion in exon 12 was conÞ rmed by cSBH. In addition, we found polymorphism in the 3'UTR region (Ex 26, nucleotide 8900 (G!A)) in sample 2, 3, 37, 73, and another polymorphism in the 3'UTR region at nucleotide 8519 A!G in sample 3.
The correct genotyping of a patient (sample 95) and an obligate carrier (sample 73) with 2-bp deletions starting at codons 2275 and 49, respectively, was accomplished using a more advanced version of the software.
We also analyzed samples of 7 haemophilic patients with unknown mutations, who were excluded to carry one of the common HA mutations, inversion of the intron 22 or intron 1. In this setting, we have found a previously undetected missense mutation Leu1843Thr in exon 16 in the sample P25. The mutation was then conÞ rmed by direct gene sequencing. In sample R32 we found another polymorphic change in Ex 23 (Ser 2182 His). In addition, we found a polymorphism in the 3'UTR region (Ex 26, nucleotide 8900 (G!A)) in sample P21, Cz1,Cz13 and Cz34 and Cz36 and another polymorphism in the 3'UTR region at nucleotide 
Discussion
We demonstrated that cSBH, and the related HyChip product, is capable of identifying a range of point mutations located within the FVIII gene making this platform an attractive alternative to standard sequencing methods.
We conÞ rmed known FVIII gene mutations and found that large regions of genomic DNA can be sequenced with excellent readability using only one HyChip array.
Because the maximal length of a single PCR product that could be sequenced by the chip is 1.2 kb in size, long exons such as exons 14 and 26 had to be divided in three and two fragments, respectively. The other exons are shorter and could be sequenced in entirety. cSBH sequence data showed 100% accuracy with only 0.2% of bases not called. [10] In addition, we demonstrated that the smaller exons 1-25 could be pooled together in groups in a manner allowing their complete sequencing on four different chips, with base readability of 100% and an accuracy of 100%.
The reliability of this technique has been further provided by analyzing a series of HA patients in whom no gene mutation was detected by the Þ rst FVIII gene screening, using common strategies (SSCP, DGGE, or dHPLC). This approach was able to identify a new point mutation (Leu1843Thr), which was subsequently conÞ rmed by direct gene sequencing. In the remaining patients, no mutation was found also when the direct gene sequencing approach was applied. Finally, how well this technique does work was provided by the identiÞ cation of the mutant allele in a heterozygous carrier with one normal factor VIII gene.
Recently, a different approach using a microarray technology has been applied for the detection of FVIII gene mutations. [14] As compared with that, the method we used was able to screen all exons using universal probes, Universal arrays use probes shorter than gene speciÞ c arrays. As a consequence, there is a higher chance to have repeated sequences longer than the length of probes (currently 11-mers in cSBH) occurring in a DNA sample. Such sequences may lead to uncertainty in the sequence assembly. For example, a stretch of 12
As can be perceived as 11, 12, 13, or more As. Also, a mutation in the middle of a repeated 20-mer or any longer segment may not be assigned to the actual copy of the repeat. This situation can be avoided by amplicon design that separates repeats into two sequencing reactions.
Short identical repeats several bases in length or longer imperfect repeats, both found in exons or immediate intronic sequences that ß ank each exon, usually do not confuse the advanced base-calling software.
There are limitations with cSBH analysis: the current software and probe set must be improved to detect DNA alterations within simple repeat regions, which is a problem common to other sequence technologies as well.
[10]
Another potential complication, which is common to other high resolution methods, including standard Sanger sequencing, is that all sequence changes, polymorphisms and missense changes that do not result in an obvious pathogenic mutation such as a stop codon and are of unknown clinical signiÞ cance will be detected.
In summary, mutation detection for the FVIII gene 
